Designing liposomes as vaccine adjuvants

Malou Henriksen-Lacey, Yvonne Perrie

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The most important perquisite in modern-day prophylactic vaccine development is the production of safe, nonreverting vaccines. To do this there has been a distinct move towards peptide or protein antigen-based vaccines, which are incapable of becoming virulent or mutating. However, whilst such vaccines appear desirable on paper, they are generally poorly immunogenic. Consequently, there has been intense development in the field of adjuvants and delivery systems, which are capable of fulfilling two important functions: firstly that antigen is delivered to an immunologically relevant cell, and secondly that antigen is recognised as being immunogenic and subsequently processed.Whilst many adjuvants are successful at ticking one of these parameters, few can act as the combined immunostimulatory delivery systems. Liposomes are among some of the successful formulations, which have been pursued as clinically relevant adjuvants (equally there are many liposome formulations which have been ignored due to their inability to be both delivery vehicle and immunostimulatory). However, in this chapter we will focus on the successful design of adjuvantal liposomes, which are of interest to vaccine developers focusing on life-threatening diseases of both the developing and developed world. Particular emphasis will be given to structural considerations and how varying these have an effect on the observed immunological outcome, measured in either in vitro, in vivo or ex vivo studies.

LanguageEnglish
Title of host publicationImmunomic Discovery of Adjuvants and Candidate Subunit Vaccines
Place of PublicationNew York
Pages181-203
Number of pages23
ISBN (Electronic)9781461450702
DOIs
Publication statusPublished - 1 Jan 2013

Publication series

NameImmunomics Reviews
PublisherSpringer
Volume5

Fingerprint

Liposomes
Vaccines
Antigens
Peptides
Proteins

Keywords

  • liposomes
  • liposomal formulation
  • cationic lipid
  • cationic liposome
  • vaccine delivery
  • microneedle array

Cite this

Henriksen-Lacey, M., & Perrie, Y. (2013). Designing liposomes as vaccine adjuvants. In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines (pp. 181-203). (Immunomics Reviews; Vol. 5). New York. https://doi.org/10.1007/978-1-4614-5070-2_10
Henriksen-Lacey, Malou ; Perrie, Yvonne. / Designing liposomes as vaccine adjuvants. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. New York, 2013. pp. 181-203 (Immunomics Reviews).
@inbook{6de2856400d840108ade09a989a99e7a,
title = "Designing liposomes as vaccine adjuvants",
abstract = "The most important perquisite in modern-day prophylactic vaccine development is the production of safe, nonreverting vaccines. To do this there has been a distinct move towards peptide or protein antigen-based vaccines, which are incapable of becoming virulent or mutating. However, whilst such vaccines appear desirable on paper, they are generally poorly immunogenic. Consequently, there has been intense development in the field of adjuvants and delivery systems, which are capable of fulfilling two important functions: firstly that antigen is delivered to an immunologically relevant cell, and secondly that antigen is recognised as being immunogenic and subsequently processed.Whilst many adjuvants are successful at ticking one of these parameters, few can act as the combined immunostimulatory delivery systems. Liposomes are among some of the successful formulations, which have been pursued as clinically relevant adjuvants (equally there are many liposome formulations which have been ignored due to their inability to be both delivery vehicle and immunostimulatory). However, in this chapter we will focus on the successful design of adjuvantal liposomes, which are of interest to vaccine developers focusing on life-threatening diseases of both the developing and developed world. Particular emphasis will be given to structural considerations and how varying these have an effect on the observed immunological outcome, measured in either in vitro, in vivo or ex vivo studies.",
keywords = "liposomes, liposomal formulation, cationic lipid, cationic liposome, vaccine delivery, microneedle array",
author = "Malou Henriksen-Lacey and Yvonne Perrie",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-5070-2_10",
language = "English",
isbn = "9781461450696",
series = "Immunomics Reviews",
publisher = "Springer",
pages = "181--203",
booktitle = "Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines",

}

Henriksen-Lacey, M & Perrie, Y 2013, Designing liposomes as vaccine adjuvants. in Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. Immunomics Reviews, vol. 5, New York, pp. 181-203. https://doi.org/10.1007/978-1-4614-5070-2_10

Designing liposomes as vaccine adjuvants. / Henriksen-Lacey, Malou; Perrie, Yvonne.

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. New York, 2013. p. 181-203 (Immunomics Reviews; Vol. 5).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Designing liposomes as vaccine adjuvants

AU - Henriksen-Lacey, Malou

AU - Perrie, Yvonne

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The most important perquisite in modern-day prophylactic vaccine development is the production of safe, nonreverting vaccines. To do this there has been a distinct move towards peptide or protein antigen-based vaccines, which are incapable of becoming virulent or mutating. However, whilst such vaccines appear desirable on paper, they are generally poorly immunogenic. Consequently, there has been intense development in the field of adjuvants and delivery systems, which are capable of fulfilling two important functions: firstly that antigen is delivered to an immunologically relevant cell, and secondly that antigen is recognised as being immunogenic and subsequently processed.Whilst many adjuvants are successful at ticking one of these parameters, few can act as the combined immunostimulatory delivery systems. Liposomes are among some of the successful formulations, which have been pursued as clinically relevant adjuvants (equally there are many liposome formulations which have been ignored due to their inability to be both delivery vehicle and immunostimulatory). However, in this chapter we will focus on the successful design of adjuvantal liposomes, which are of interest to vaccine developers focusing on life-threatening diseases of both the developing and developed world. Particular emphasis will be given to structural considerations and how varying these have an effect on the observed immunological outcome, measured in either in vitro, in vivo or ex vivo studies.

AB - The most important perquisite in modern-day prophylactic vaccine development is the production of safe, nonreverting vaccines. To do this there has been a distinct move towards peptide or protein antigen-based vaccines, which are incapable of becoming virulent or mutating. However, whilst such vaccines appear desirable on paper, they are generally poorly immunogenic. Consequently, there has been intense development in the field of adjuvants and delivery systems, which are capable of fulfilling two important functions: firstly that antigen is delivered to an immunologically relevant cell, and secondly that antigen is recognised as being immunogenic and subsequently processed.Whilst many adjuvants are successful at ticking one of these parameters, few can act as the combined immunostimulatory delivery systems. Liposomes are among some of the successful formulations, which have been pursued as clinically relevant adjuvants (equally there are many liposome formulations which have been ignored due to their inability to be both delivery vehicle and immunostimulatory). However, in this chapter we will focus on the successful design of adjuvantal liposomes, which are of interest to vaccine developers focusing on life-threatening diseases of both the developing and developed world. Particular emphasis will be given to structural considerations and how varying these have an effect on the observed immunological outcome, measured in either in vitro, in vivo or ex vivo studies.

KW - liposomes

KW - liposomal formulation

KW - cationic lipid

KW - cationic liposome

KW - vaccine delivery

KW - microneedle array

UR - http://www.scopus.com/inward/record.url?scp=84944270830&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-5070-2_10

DO - 10.1007/978-1-4614-5070-2_10

M3 - Chapter

SN - 9781461450696

T3 - Immunomics Reviews

SP - 181

EP - 203

BT - Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

CY - New York

ER -

Henriksen-Lacey M, Perrie Y. Designing liposomes as vaccine adjuvants. In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. New York. 2013. p. 181-203. (Immunomics Reviews). https://doi.org/10.1007/978-1-4614-5070-2_10